Sanofi the French pharmaceutical company has agreed to purchase Blueprint Medicines Corporation based in the United States for a maximum of $9.5 billion to enhance its rare immunology disease capabilities. The initial cash payment amounts to $9.1 billion through $129.00 per share while additional milestone payments could increase the total value to $9.5 billion.
The main asset of Blueprint Medicines is Ayvakit (also known as Ayvakyt) which holds the status of the only FDA-approved treatment for advanced and indolent systemic mastocytosis in both the U.S. and EU markets. Through this acquisition Sanofi gains access to two promising candidates elenestinib and BLU-808 which will enhance their pipeline.
Sanofi CEO Paul Hudson stated that this acquisition brings strategic benefits to our rare and immunology portfolios. The acquisition strengthens our pipeline and drives our mission to become the world leader in immunology.
The acquisition will become effective during the third quarter after receiving necessary regulatory approvals and shareholder consent. Sanofi has continued its immunology portfolio expansion through its recent acquisitions of Vigil Neuroscience and Inhibrx.
